Business, energy, technology, markets and global industry news from Business News Today

ORKA-001

PharmaDeviceNews ORKA-001
Representative image of plaque psoriasis treatment as Oruka Therapeutics’ ORKA-001 achieves 61% complete skin clearance in a positive Phase 2b EVERLAST-B clinical trial.
Pharma & Biotech

ORKA-001 shows strong psoriasis skin-clearance results as pivotal trials approach in 2027

Oruka Therapeutics' ORKA-001 achieves 61% complete skin clearance in Phase 2b psoriasis testing. Explore the results and Phase 3 plans.

Read More
Representative image: A biotech laboratory scene showing injectable biologic formulation work, reflecting how the Halozyme Therapeutics and Oruka Therapeutics Hypercon agreement could shape the next phase of long-acting psoriasis drug delivery.
Pharma & Biotech

Why Halozyme’s Hypercon deal with Oruka could matter beyond one psoriasis antibody

Psoriasis biologics are getting longer acting. Halozyme and Oruka now face the harder test of making high-dose therapy practical.

Read More